To mark the tenth anniversary of Nature Reviews Drug Discovery, this collection brings together analysis of data and trends in the field over the past decade, and a selection of some of the most highly cited and downloaded articles published in the journal from each of the last 10 years.
2012
Editorial: A decade in drug discovery
doi:10.1038/nrd3648
Nature Reviews Drug Discovery 11, 1 (2012)
Nature Reviews Drug Discovery marks its tenth anniversary, providing an opportunity to reflect on the evolution of the landscape of drug research and development.
From the analyst's couch: A decade of change
doi:10.1038/nrd3630
Nature Reviews Drug Discovery 11, 17 (2012)
Data on indicators such as the number and success rate of research and development projects illustrate trends in the pharmaceutical industry over the past decade.
Patent watch: Key patent-related events of the past 10 years
doi:10.1038/nrd3641
Nature Reviews Drug Discovery 11, 12 (2012)
Our patent advisors provide their views on the most noteworthy patent-related events related to drug discovery and development in the past decade.
2011
How were new medicines discovered?
David C. Swinney & Jason Anthony
doi:10.1038/nrd3480
Nature Reviews Drug Discovery 10, 507-519 (2011)
Observations from this analysis of the discovery strategies for a decade of new drugs approved by the US FDA, such as a higher than expected contribution of phenotypic screening to the discovery of first-in-class drugs, could have important implications for efforts to increase pharmaceutical industry productivity.
2010
Membrane transporters in drug development
The International Transporter Consortium
doi:10.1038/nrd3028
Nature Reviews Drug Discovery 9, 215-236 (2010)
Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs; this article provides the recommendations of a group drawn from academia, industry and regulatory authorities on how to incorporate this knowledge into clinical development.
2009
Knocking down barriers: advances in siRNA delivery
Kathryn A. Whitehead, Robert Langer & Daniel G. Anderson
doi:10.1038/nrd2742
Nature Reviews Drug Discovery 8, 129-138 (2009)
Realizing the therapeutic potential of RNA interference, one of the hottest research fields over the past decade, requires clinically suitable, safe and effective drug delivery vehicles, the development of which is discussed in this article.
2008
Structural diversity of G protein-coupled receptors and significance for drug discovery
Malin C. Lagerström & Helgi B. Schiöth
doi:10.1038/nrd2518
Nature Reviews Drug Discovery 7, 339-357 (2008)
This article provided a comprehensive overview of human G protein-coupled receptors — the largest family of membrane-bound receptors and also the targets of many drugs — including ligand preference, common and unique structural features and the potential for future drug discovery.
2007
Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
doi:10.1038/nrd2115
Nature Reviews Drug Discovery 6, 273-286 (2007)
The idea of targeting tumour angiogenesis as an anticancer strategy was first put forward by Judah Folkman four decades ago; here he discussed new directions in the burgeoning field of angiogenesis research in multiple therapeutic areas.
2006
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden, Melissa J. Peart & Ricky W. Johnstone
doi:10.1038/nrd2133
Nature Reviews Drug Discovery 5, 769-784 (2006)
Enzymes involved in the epigenetic regulation of gene expression, such as histone deacetylases, have been among the therapeutic targets attracting the most interest in the past decade; this article discussed the molecular basis of the anticancer activities of histone deacetylase inhibitors.
2005
Recent advances with liposomes as pharmaceutical carriers
Vladimir P. Torchilin
doi:10.1038/nrd1632
Nature Reviews Drug Discovery 4, 145-160 (2005)
This article reviewed the wide-ranging opportunities for the application of liposomes — microscopic phospholipid bubbles with a bilayered membrane structure — in drug delivery.
2004
Can the pharmaceutical industry reduce attrition rates?
Ismail Kola & John Landis
doi:10.1038/nrd1470
Nature Reviews Drug Discovery 3, 711-716 (2010)
As well as presenting widely cited data on variations in attrition rates between therapeutic areas and across different stages of drug discovery and development, this article put forward potential strategies to improve pharmaceutical industry productivity.
2003
The dawning era of polymer therapeutics
Ruth Duncan
doi:10.1038/nrd1088
Nature Reviews Drug Discovery 2, 347-360 (2003)
This article highlighted research at the interface of polymer chemistry and biomedical science that continues to lead to advances in the application of nanotechnology in medicine.
2002
The druggable genome
Andrew L. Hopkins & Colin R. Groom
doi:10.1038/nrd892
Nature Reviews Drug Discovery 1, 727-730 (2002)
Shortly after the publication of the human genome sequence, Hopkins and Groom provided a pioneering analysis of the number and nature of potential drug targets encoded within it.
© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.
